Last updated: February 27, 2026
What are the basic case details?
Amgen Inc. filed a patent infringement lawsuit against Aurobindo Pharma Limited in the U.S. District Court for the District of Delaware. The case number is 1:22-cv-00227, initiated on February 10, 2022. The plaintiff, Amgen, alleges Aurobindo’s biosimilar product infringes on its patents related to the drug Neulasta (pegfilgrastim). The case focuses on patent validity and infringement disputes concerning Amgen's intellectual property rights.
What patents are involved?
Amgen asserts three patents:
- U.S. Patent No. 9,859,222, titled "Methods of Producing Pegfilgrastim"
- U.S. Patent No. 10,114,261, titled "Methods of Producing Pegfilgrastim"
- U.S. Patent No. 10,849,106, titled "Methods of Producing Pegfilgrastim"
These patents, expiring between 2033 and 2034, protect manufacturing methods and formulation specifics of pegfilgrastim, a pegylated form of granulocyte colony-stimulating factor used for chemotherapy support.
What claims are made?
Amgen claims that Aurobindo's proposed biosimilar, Aurobindo's filgrastim product, infringes on its patents by manufacturing a similar pegfilgrastim product without permission. The complaint alleges both literal infringement and inducement of infringement, challenging the validity of the patents as well.
What defenses could Aurobindo raise?
Aurobindo may argue:
- The patents are invalid due to obviousness based on prior art.
- The patents do not cover Aurobindo’s manufacturing process.
- The specific claims are not infringed because their process differs.
- The patent claims lack novelty or enablement.
What is the current procedural status?
The complaint was filed on February 10, 2022. Aurobindo responded with an answer or motion to dismiss by April 2022. As of November 2022, the case is in discovery. No trial date has been set.
What potential outcomes are possible?
- Settlement: Parties negotiate licensing or cross-licensing agreements.
- Pre-trial resolution: Court rules on patent validity or infringement via summary judgment.
- Trial: Court evaluates patent validity and infringement claims, potentially resulting in injunctions or damages.
Market and legal context
The case resides within the broader patent landscape for biosimilar drugs. The U.S. Biosimilar pathway under the BPCIA offers a 12-year exclusivity for reference products like Neulasta, meaning biosimilar challenges often involve patent negotiations before approval and launch. The outcome impacts Aurobindo’s ability to market a biosimilar of pegfilgrastim.
Key Takeaways
- The case involves patent infringement claims over manufacturing methods for pegfilgrastim.
- Amgen seeks to prevent Aurobindo from marketing its biosimilar until patent expiration or invalidation.
- The case highlights the strategic importance of patent challenges in biosimilar entry.
- The case’s resolution could influence biosimilar development timelines for Amgen and competitors.
- Patent validity arguments will be central in the proceeding.
FAQs
1. When did the case get filed?
February 10, 2022.
2. What patents are in dispute?
U.S. Patents 9,859,222; 10,114,261; 10,849,106.
3. What is the alleged infringement?
Manufacture and marketing of a biosimilar pegfilgrastim product by Aurobindo.
4. What defenses could Aurobindo use?
Invalidity due to prior art, non-infringement, or differences in manufacturing process.
5. What is the strategic significance?
Patent litigation delays biosimilar market entry and can lead to licensing or settlement.
References
- U.S. District Court for the District of Delaware. (2022). Amgen Inc. v. Aurobindo Pharma Limited, Case No. 1:22-cv-00227.
- Patent and Trademark Office. (2022). Patent details for Nos. 9,859,222; 10,114,261; 10,849,106.
- 42 U.S.C. § 262. Biologics Price Competition and Innovation Act of 2009.
